Experimental Hematology & Oncology

Article	Citations
Prospective pharmacotyping of urothelial carcinoma organoids for drug sensitivity prediction – feasibility and real world experience	175
Targeting ST8SIA6-AS1 counteracts KRASG12C inhibitor resistance through abolishing the reciprocal activation of PLK1/c-Myc signaling	157
Cardiotoxicity of small-molecule kinase inhibitors in cancer therapy	148
The emerging scenario of immunotherapy for T-cell Acute Lymphoblastic Leukemia: advances, challenges and future perspectives	130
cGAS-ISG15-RAGE axis reprogram necroptotic microenvironment and promote lymphatic metastasis in head and neck cancer	123
A correlation of ineffective erythropoiesis and dysregulated signaling pathways in myelodysplastic syndromes/neoplasms	105
MENIN inhibitor-based therapy in acute leukemia: latest updates from the 2024 ASH annual meeting	95
Next-generation sequencing for MRD monitoring in B-lineage malignancies: from bench to bedside	72
Mitotic MTH1 inhibitor karonudib kills epithelial ovarian cancer independent of platinum sensitivity	72
Cytokine-based models for efficient differentiation between infection and cytokine release syndrome in patients with hematological malignancies	71
Suppression of CYLD by HER3 confers ovarian cancer platinum resistance via inhibiting apoptosis and by inducing drug efflux	71
Fecal microbiota transplantation combined with ruxolitinib as a salvage treatment for intestinal steroid-refractory acute GVHD	67
New insights into epigenetic regulation of resistance to PD-1/PD-L1 blockade cancer immunotherapy: mechanisms and therapeutic opportunities	66
Telomeres, telomerase, and cancer: mechanisms, biomarkers, and therapeutics	65
Current approaches to develop “off-the-shelf” chimeric antigen receptor (CAR)-T cells for cancer treatment: a systematic review	65
Efficacy and safety of immune checkpoint inhibitors in metastatic penile squamous cell carcinoma: a retrospective multicenter analysis	60
Correction: Unraveling the structures, functions and mechanisms of epithelial membrane protein family in human cancers	59
Myeloid-derived suppressor cells in hematologic malignancies: two sides of the same coin	56
Breast cancer heterogeneity and its implication in personalized precision therapy	55
Exploiting E3 ubiquitin ligases to reeducate the tumor microenvironment for cancer therapy	55
Targeting hepcidin in colorectal cancer triggers a TNF-dependent-gasdermin E-driven immunogenic cell death response	53
All-in-one CRISPR/Cas-engineered glucocorticoid-receptor knock-out EBV-gp350-CAR knock-in T cells are potent and resistant to dexamethasone	50
Selinexor in combination with standard chemotherapy in patients with advanced or metastatic solid tumors	50
Tumor battlefield within inflamed, excluded or desert immune phenotypes: the mechanisms and strategies	48
Correction: Breast cancer heterogeneity and its implication in personalized precision therapy	48

Multi-omic profiling of the leukemic microenvironment shows bone marrow interstitial fluid is distinct from peripheral blood plasma	46
HIV associated lymphoma: latest updates from 2023 ASH annual meeting	46
Recent updates on central nervous system prophylaxis in patients with high-risk diffuse large B-cell lymphoma	45
Role of m6A writers, erasers and readers in cancer	44
Emerging therapeutic frontiers in cancer: insights into posttranslational modifications of PD-1/PD-L1 and regulatory pathways	42
Single-cell transcriptome analysis reveals stem cell-like subsets in the progression of Waldenström’s macroglobulinemia	41
Enhanced cellular therapy: revolutionizing adoptive cellular therapy	41
Novel agents and regimens in relapsed or refractory peripheral T-cell lymphoma: latest updates from 2023 ASH annual meeting	39
Therapeutic synergy of Triptolide and MDM2 inhibitor against acute myeloid leukemia through modulation of p53-dependent and -independent pathways	39
Three-dimensional chromatin landscapes in MLLr AML	39
CD19/CD22 CAR-T-cell cocktail therapy following autologous transplantation is an optimizing strategy for treating relapsed/refractory central nervous system lymphoma	39
IL-39 promotes chronic graft-versus-host disease by increasing T and B Cell pathogenicity	38
Hetrombopag plus porcine ATG and cyclosporine for the treatment of aplastic anaemia: early outcomes of a prospective pilot study	36
CAR-macrophages targets CD26 to eliminate chronic myeloid leukemia stem cells	35
Matching-adjusted indirect comparison of efficacy and safety of lisocabtagene maraleucel and mosunetuzumab for the treatment of third-line or later relapsed or refractory follicular lymphoma	34
Modified dendritic cell-derived exosomes activate both NK cells and T cells through the NKG2D/NKG2D-L pathway to kill CML cells with or without T315I mutation	34
Correction: Efficacy of NKG2D CAR-T cells with IL-15/IL-15Rα signaling for treating Epstein-Barr virus-associated lymphoproliferative disorder	33
TCR engineered T cells for solid tumor immunotherapy	33
The natural FGF-trap long pentraxin 3 inhibits lymphangiogenesis and lymphatic dissemination	32
Hepatitis B surface antigen: carcinogenesis mechanisms and clinical implications in hepatocellular carcinoma	31
circRanGAP1/miR-27b-3p/NRAS Axis may promote the progression of hepatocellular Carcinoma	31
IHCH9033, a novel class I HDAC inhibitor, synergizes with FLT3 inhibitor and rescues quizartinib resistance in FLT3-ITD AML via enhancing DNA damage response	31
IPSS-M has greater survival predictive accuracy compared with IPSS-R in persons ≥ 60 years with myelodysplastic syndromes	30
Metabolic cross-talk within the bone marrow milieu: focus on multiple myeloma	30
Myelodysplastic syndromes are multiclonal diseases derived from hematopoietic stem and progenitor cells	30
Therapeutic activation of G protein-coupled estrogen receptor 1 in Waldenström Macroglobulinemia	30
Targeting NRF2 uncovered an intrinsic susceptibility of acute myeloid leukemia cells to ferroptosis	29
The development and application of chimeric antigen receptor natural killer (CAR-NK) cells for cancer therapy: current state, challenges and emerging therapeutic advances	28
Matching-adjusted indirect treatment comparison of chimeric antigen receptor T-cell therapies for third-line or later treatment of relapsed or refractory large B-cell lymphoma: lisocabtagene maraleuce	28
Crosstalk between colorectal CSCs and immune cells in tumorigenesis, and strategies for targeting colorectal CSCs	28
Red blood cells differentiated in vitro using sequential liquid and semi-solid culture as a pre-clinical model	28
Vaccination with a combination of STING agonist-loaded lipid nanoparticles and CpG-ODNs protects against lung metastasis via the induction of CD11bhighCD27low memory-like NK cells	28
A one-base therapeutic insertion in the HBG2 distal promoter reactivates γ-globin expression	27
Preclinical investigations and a first-in-human phase 1a trial of JS007, a novel anti-CTLA-4 antibody, in patients with advanced solid tumors	27
Disparities in the incidence, mortality and disability-adjusted life years of 33 early-onset cancer groups globally, 2012–2021: a systematic analysis	27
New exploration of KRASG12D inhibitors and the mechanisms of resistance	27
Antibody-drug conjugates in breast cancer: current evidence and future directions	26
Immunotherapy in breast cancer: current landscape and emerging trends	26
Recent advances and future perspectives in the therapeutics of prostate cancer	26
CD47xCD19 bispecific antibody triggers recruitment and activation of innate immune effector cells in a B-cell lymphoma xenograft model	25
Versatile function of NF-ĸB in inflammation and cancer	25
Targeting secretory autophagy in solid cancers: mechanisms, immune regulation and clinical insights	25
A comprehensive model to predict severe acute graft-versus-host disease in acute leukemia patients after haploidentical hematopoietic stem cell transplantation	25
Construction of CD19 targeted dual- and enhanced dual-antibodies and their efficiency in the treatment of B cell malignancy	23
Impact of diagnosis to treatment interval on outcomes in patients with newly diagnosed marginal zone lymphoma - a US multisite study	23
The clinical impact of IKZF1 mutation in acute myeloid leukemia	23
Crosstalk between O-GlcNAcylation and ubiquitination: a novel strategy for overcoming cancer therapeutic resistance	23
Mechanistic insights and the clinical prospects of targeted therapies for glioblastoma: a comprehensive review	22
Chimeric antigen receptor-engineered NK cells: new weapons of cancer immunotherapy with great potential	22
Association between abnormal lipid profile and inflammation and progression of myelodysplastic syndrome to acute leukemia	22

CRISPR/Cas9 technology for advancements in cancer immunotherapy: from uncovering regulatory mechanisms to therapeutic applications	22
Immune-related gene index predicts metastasis for prostate cancer patients undergoing radical radiotherapy	22
Antitumor effect of a small-molecule inhibitor of KRASG12D in xenograft models of mucinous appendicular neoplasms	22
Efficacy of NKG2D CAR-T cells with IL-15/IL-15Rα signaling for treating Epstein-Barr virus-associated lymphoproliferative disorder	21
Whole-exome sequencing analysis identifies distinct mutational profile and novel prognostic biomarkers in primary gastrointestinal diffuse large B-cell lymphoma	21
The CD64/CD28/CD3ζ chimeric receptor reprograms T-cell metabolism and promotes T-cell persistence and immune functions while triggering antibody-independent and antibody-dependent cytotoxicity	21
Combinatorial functionomics identifies HDAC6-dependent molecular vulnerability of radioresistant head and neck cancer	21
Preclinical activity of selinexor in combination with eribulin in uterine leiomyosarcoma	21
Tunlametinib (HL-085) plus vemurafenib in patients with advanced BRAF V600-mutant solid tumors: an open-label, single-arm, multicenter, phase I study	20
Validation of a microRNA profile in urine liquid biopsy with diagnostic and stratification value for bladder cancer classification, available through the open app BladdermiRaCan	20
Downregulation of pro-surfactant protein B contributes to the recurrence of early-stage non-small cell lung cancer by activating PGK1-mediated Akt signaling	20
Immunotherapy in chronic lymphocytic leukemia: advances and challenges	19
A novel AML1-ETO/FTO positive feedback loop promotes leukemogenesis and Ara-C resistance via stabilizing IGFBP2 in t(8;21) acute myeloid leukemia	19
A novel and efficient CD22 CAR-T therapy induced a robust antitumor effect in relapsed/refractory leukemia patients when combined with CD19 CAR-T treatment as a sequential therapy	19
CD28 is superior to 4-1BB costimulation in generating CAR-NK cells for tumor immunotherapy	19
DLC1 deficiency at diagnosis predicts poor prognosis in acute myeloid leukemia	19
Venetoclax-based therapy for relapsed or refractory acute myeloid leukemia: latest updates from the 2022 ASH annual meeting	19
Correction: New insights into epigenetic regulation of resistance to PD-1/PD-L1 blockade cancer immunotherapy: mechanisms and therapeutic opportunities	18
Chinese expert consensus on Bruton tyrosine kinase inhibitors in the treatment of B-cell malignancies	18
Sarcosine sensitizes lung adenocarcinoma to chemotherapy by dual activation of ferroptosis via PDK4/PDHA1 signaling and NMDAR-mediated iron export	18
Correction to: Bispecific antibodies and dual-targeting CAR-T cells for multiple myeloma: latest updates from the 2023 ASCO annual meeting	18
Single-cell analysis defines highly specific leukemia-induced neutrophils and links MMP8 expression to recruitment of tumor associated neutrophils during FGFR1 driven leukemogenesis	18
The roles of tissue resident macrophages in health and cancer	18
Adefovir dipivoxil inhibits APL progression through degradation of the oncoprotein PML-RARA	18
The role of pyroptosis and gasdermin family in tumor progression and immune microenvironment	18
Incidence, mortality, and risk factors of bladder, kidney, prostate and testicular cancers in China and comparisons with the United States, the United Kingdom, Japan, and the Republic of Korea: an up-	18
Decoding leukemia at the single-cell level: clonal architecture, classification, microenvironment, and drug resistance	17
Advances in adoptive cellular immunotherapy and therapeutic breakthroughs in multiple myeloma	17
Chimeric antigen receptor-T cell therapy for T cell-derived hematological malignancies	17
Progression patterns in monoclonal gammopathy of undetermined significance and multiple myeloma outcome: a cohort study in 42 patients	17
Small cell lung cancer: emerging subtypes, signaling pathways, and therapeutic vulnerabilities	17
Lactylation modification in cancer: mechanisms, functions, and therapeutic strategies	16
HOXA13 promotes gastric cancer progression partially via the FN1-mediated FAK/Src axis	16
Roles of the intestinal microbiota and microbial metabolites in acute GVHD	16
Combination of percutaneous thermal ablation and adoptive Th9 cell transfer therapy against non-small cell lung cancer	16
In-depth insight into tumor-infiltrating stromal cells linked to tertiary lymphoid structures and their prospective function in cancer immunotherapy	16
Siltuximab for the treatment of early complications after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia in children, adolescents, and young adults	16
Molecular profiling of biliary tract cancers reveals distinct genomic landscapes between circulating and tissue tumor DNA	16
An ureido-substituted benzenesulfonamide carbonic anhydrase inhibitor exerts a potent antitumor effect in vitro and in vivo	16
Biomechanics in the tumor microenvironment: from biological functions to potential clinical applications	15
Molecular characterization of the CXCR4 / CXCR7 axis in germ cell tumors and its targetability using nanobody-drug-conjugates	15
Reduced morbidity and mortality of cGVHD in patients who received treatment with mesenchymal stromal cells for steroid-resistant aGVHD: long-term follow-up of a randomized phase 3 trial	15
The progress of novel strategies on immune-based therapy in relapsed or refractory diffuse large B-cell lymphoma	15
Inhibition of CDC20 potentiates anti-tumor immunity through facilitating GSDME-mediated pyroptosis in prostate cancer	15
Bladder cancer subtypes exhibit limited plasticity across different microenvironments and in metastases	15
Global burden and trends of hematologic malignancies based on Global Cancer Observatory 2022 and Global Burden of Disease 2021	15
Engineered circular RNA-based DLL3-targeted CAR-T therapy for small cell lung cancer	15
Outcomes of allogeneic hematopoietic stem cell transplantation in R/R DLBCL patients with failure of CAR-T therapy	14
A cohort-based multi-omics identifies nuclear translocation of eIF5B /PD-L1/CD44 complex as the target to overcome Osimertinib resistance of ARID1A-deficient lung adenocarcinoma	14
CUL4B-DDB1-COP1-mediated UTX downregulation promotes colorectal cancer progression	14
Improving CAR-T cell function through a targeted cytokine delivery system utilizing car target-modified extracellular vesicles	14
MMP14 from BM-MSCs facilitates progression and Ara-C resistance in acute myeloid leukemia via the JAK/STAT pathway	14
Cirrhotic-extracellular matrix attenuates aPD-1 treatment response by initiating immunosuppressive neutrophil extracellular traps formation in hepatocellular carcinoma	14
CDCA8 induced by NF-YA promotes hepatocellular carcinoma progression by regulating the MEK/ERK pathway	14
Targeting TIM-3 for hematological malignancy: latest updates from the 2022 ASH annual meeting	14
TLR7/8 signaling activation enhances the potency of human pluripotent stem cell-derived eosinophils in cancer immunotherapy for solid tumors	14
CRISPR/Cas9 system: recent applications in immuno-oncology and cancer immunotherapy	14
Pan-cancer transcriptional atlas of minimal residual disease links DUSP1 to chemotherapy persistence	13
Role of CDK4 as prognostic biomarker in Soft Tissue Sarcoma and synergistic effect of its inhibition in dedifferentiated liposarcoma sequential treatment	13
ZMIZ2 facilitates hepatocellular carcinoma progression via LEF1 mediated activation of Wnt/β-catenin pathway	13
The genomic analysis brings a new piece to the molecular jigsaw of idiopathic erythrocytosis	13
Revealing the role of the gut microbiota in enhancing targeted therapy efficacy for lung adenocarcinoma	13
Comparison of local ablative therapies, including radiofrequency ablation, microwave ablation, stereotactic ablative radiotherapy, and particle radiotherapy, for inoperable hepatocellular carcinoma: a	13
Bispecific antibodies as monotherapy or in combinations for non-hodgkin B-cell lymphoma: latest updates from the American society of hematology 2022 annual meeting	13
The role of organoids in cancer research	13
EZH2 in hepatocellular carcinoma: progression, immunity, and potential targeting therapies	12
A pan-cancer analysis of the oncogenic role of leucine zipper protein 2 in human cancer	12
Identification of adenoid subtype characterized with immune-escaped phenotype in lung squamous carcinoma based on transcriptomics	12
Outcome differences between PD-1/PD-L1 inhibitors-based monotherapy and combination treatments in NSCLC with brain metastases	12
AOH1996 targets mitochondrial dynamics and metabolism in leukemic stem cells via mitochondrial PCNA inhibition	12
RNA binding proteins in MLL-rearranged leukemia	12
Elevated expression of the RNA-binding protein IGF2BP1 enhances the mRNA stability of INHBA to promote the invasion and migration of esophageal squamous cancer cells	12
19-Hydroxybufalin inhibits non-small cell lung cancer cell proliferation and promotes cell apoptosis via the Wnt/β-catenin pathway	12
Hypomethylating agents plus venetoclax for high-risk MDS and CMML as bridge therapy to transplant: a GESMD study	12
The role of neutrophil extracellular traps in cancer progression, metastasis and therapy	11
Trends in platelet count among cancer patients	11
Multidisciplinary recommendations for the management of CAR-T recipients in the post-COVID-19 pandemic era	11
Surface TREM2 on circulating M-MDSCs as a novel prognostic factor for adults with treatment-naïve diffuse large B-cell lymphoma	11
Comprehensive antitumor immune response boosted by dual inhibition of SUMOylation and MEK in MYC-expressing KRAS-mutant cancers	11
Molecular correlation of response to pyrotinib in advanced NSCLC with HER2 mutation: biomarker analysis from two phase II trials	11

Applications of liposomes and lipid nanoparticles in cancer therapy: current advances and prospects	11
Ubiquitin modification in the regulation of tumor immunotherapy resistance mechanisms and potential therapeutic targets	11
RHO GTPase family in hepatocellular carcinoma	11
CD44 promotes hepatocellular carcinoma progression via upregulation of YAP	11
TRIM family contribute to tumorigenesis, cancer development, and drug resistance	11
Next-generation immunotherapeutic approaches for blood cancers: Exploring the efficacy of CAR-T and cancer vaccines	11
Reconstructed colorectal cancer model to dissect the anti-tumor effect of mesenchymal stromal cells derived extracellular vesicles	11
Heterogeneity of the tumor immune microenvironment and its clinical relevance	11
Extracellular matrix stiffness: mechanisms in tumor progression and therapeutic potential in cancer	11
A bile-based microRNA signature for differentiating malignant from benign pancreaticobiliary disease	11
ProNGF promotes brain metastasis through TrkA/EphA2 induced Src activation in triple negative breast cancer cells	11
GPR68-ATF4 signaling is a novel prosurvival pathway in glioblastoma activated by acidic extracellular microenvironment	10
Analysis of CD20 and PD-L1 levels on small extracellular vesicles (sEV) produced by DLBCL cells and EBV-transformed B cells, and potential role in T cell inhibition	10
CAR-T cell combination therapies in hematologic malignancies	10
LINP1 represses unfolded protein response by directly inhibiting eIF2α phosphorylation to promote cutaneous squamous cell carcinoma	10
Secretogranin II influences the assembly and function of MHC class I in melanoma	10
Roles of N6-methyladenosine (m6A) modifications in gynecologic cancers: mechanisms and therapeutic targeting	10
METTL3 modulates m6A modification of CDC25B and promotes head and neck squamous cell carcinoma malignant progression	10
Bruton tyrosine kinase inhibitors in B-cell lymphoma: beyond the antitumour effect	10
Chidamide and apatinib are therapeutically synergistic in acute myeloid leukemia stem and progenitor cells	10
Transfer RNA-derived small RNA: an emerging small non-coding RNA with key roles in cancer	10
Unravelling neutropenic enterocolitis: insights from gut microbiota, and intestinal barrier analyses	10
Ferroptosis: a novel regulated cell death participating in cellular stress response, radiotherapy, and immunotherapy	10
ANXA6/TRPV2 axis promotes lymphatic metastasis in head and neck squamous cell carcinoma by inducing autophagy	10
Phase 2 trial of intravenous oncolytic virus JX-594 combined with low-dose cyclophosphamide in patients with advanced breast cancer	10
The gut microbiota as a booster for radiotherapy: novel insights into radio-protection and radiation injury	10
Current advances and challenges in CAR T-Cell therapy for solid tumors: tumor-associated antigens and the tumor microenvironment	9
Current insight into the regulation of PD-L1 in cancer	9
Identification of a novel NPM1 mutation in acute myeloid leukemia	9
VISTA drives macrophages towards a pro-tumoral phenotype that promotes cancer cell phagocytosis yet down-regulates T cell responses	9
A Pig-a conditional knock-out mice model mediated by Vav-iCre: stable GPI-deficient and mild hemolysis	9
Generation and clinical potential of functional T lymphocytes from gene-edited pluripotent stem cells	9
Vertical targeting of the PI3K/AKT pathway at multiple points is synergistic and effective for non-Hodgkin lymphoma	9
Platelets in cancer and immunotherapy: functional dynamics and therapeutic opportunities	9
Application patterns and outcomes of hematopoietic stem cell transplantation in peripheral T-cell lymphoma patients: a multicenter real-world study in China	9
Healing of lytic lesions and restoration of bone health in multiple myeloma through sclerostin inhibition	9
Progress in understanding the mechanisms of resistance to BCL-2 inhibitors	9
Molecular profiling of skin cells identifies distinct cellular signatures in radiation-induced skin injury across various stages in the murine dataset	9
Recent advances and challenges of cellular immunotherapies in lung cancer treatment	9
Radiation-induced exosomal miR-21 enhances tumor proliferation and invasiveness in breast cancer: implications for poor prognosis in radiotherapy patients	9
p53 directly downregulates the expression of CDC20 to exert anti-tumor activity in mantle cell lymphoma	8
Targeting NOTCH1 in combination with antimetabolite drugs prolongs life span in relapsed pediatric and adult T-acute lymphoblastic leukemia xenografts	8
Novel cellular immunotherapies for hematological malignancies: recent updates from the 2021 ASH annual meeting	8
Targeting collagen to optimize cancer immunotherapy	8
Distinct response to IL-1β blockade in liver- and lung-specific metastasis mouse models of pancreatic cancer with heterogeneous tumor microenvironments	8
Multi-omics analyses of the heterogenous immune microenvironment in triple-negative breast cancer implicate UQCRFS1 potentiates tumor progression	8
Efficacy of combination of venetoclax with azacitidine or chemotherapy in refractory/relapse acute leukemias of ambiguous lineage, not otherwise specified	8
The clinical landscape of CAR NK cells	8
Roles of tumor-associated macrophages in tumor progression: implications on therapeutic strategies	8
Infusion and delivery strategies to maximize the efficacy of CAR-T cell immunotherapy for cancers	8
Bisecting GlcNAc enhances CD8+ T cell-mediated killing of breast cancer by suppressing PD-L1 expression and its binding to PD-1	8
Genetic factors, risk prediction and AI application of thrombotic diseases	8
Current and future therapies for follicular lymphoma	8
New insight into circRNAs: characterization, strategies, and biomedical applications	8
Targeting metabolic reprogramming in chronic lymphocytic leukemia	7
CD105+CAF-derived exosomes CircAMPK1 promotes pancreatic cancer progression by activating autophagy	7
Therapeutic targets of armored chimeric antigen receptor T cells navigating the tumor microenvironment	7
Dual-targeted CAR T-cell immunotherapies for hematological malignancies: latest updates from the 2023 ASH annual meeting	7
Addressing graft-versus-host disease in allogeneic cell-based immunotherapy for cancer	7
Bone marrow sympathetic neuropathy is a hallmark of hematopoietic malignancies and it involves severe ultrastructural damage	7
New approaches to idiopathic neutropenia in the era of clonal hematopoiesis	7
Increasing cure rates of solid tumors by immune checkpoint inhibitors	7
Prophylactic infusion of allogeneic double-negative T cells as immune modulators to prevent relapse in high-risk AML patients post-Allo-HSCT: a phase I trial	7
Thioredoxin-1 regulates self-renewal and differentiation of murine hematopoietic stem cells through p53 tumor suppressor	7
Myeloid-derived suppressor cells in cancer: therapeutic targets to overcome tumor immune evasion	7
The GPIb-IX complex on platelets: insight into its novel physiological functions affecting immune surveillance, hepatic thrombopoietin generation, platelet clearance and its relevance for cancer devel	7
Developments in nanotechnology approaches for the treatment of solid tumors	7
CD7-directed CAR T-cell therapy: a potential immunotherapy strategy for relapsed/refractory acute myeloid leukemia	7
Natural killer cell-based cancer immunotherapy: from basics to clinical trials	7
Targeting CD22 for B-cell hematologic malignancies	7
Age-related accumulation of B-1 cell progenitors in mice reflects changes in miR15a/16-1 expression and radioresistance capacity	6
Deciphering tumor-infiltrating dendritic cells in the single-cell era	6
Immunosuppressive tumor microenvironment in the progression, metastasis, and therapy of hepatocellular carcinoma: from bench to bedside	6
Epigenetic alterations of TP53INP1 by EHMT2 regulate the cell cycle in gastric cancer	6
Advances and challenges in the treatment of myelodysplastic syndromes	6
Chimeric antigen receptor engineered natural killer cells for cancer therapy	6
Ubiquitin-specific protease 28: the decipherment of its dual roles in cancer development	6
The multi-CDK inhibitor dinaciclib reverses bromo- and extra-terminal domain (BET) inhibitor resistance in acute myeloid leukemia via inhibition of Wnt/β-catenin signaling	6
Metastatic clear-cell renal cell carcinoma: a frequent NOTCH1 mutation predictive of response to anti-NOTCH1 CB-103 treatment	6
Recent advances and challenges of bispecific antibodies in solid tumors	6
Targeting DNA helicase CMG complex and NFκB2-driven drug-resistant transcriptional axis to effectively treat KRASG12D-mutated pancreatic cancer	6
A new dosing regimen of ropeginterferon alfa-2b is highly effective and tolerable: findings from a phase 2 study in Chinese patients with polycythemia vera	6
ALKBH5 prevents hepatocellular carcinoma progression by post-transcriptional inhibition of PAQR4 in an m6A dependent manner	6
Extracellular matrix stiffness reduces DNA 6 ma level to facilitate colorectal cancer progression via disrupting P53 binding to CDKN1A promoter	6
CRISPR/Cas9-mediated knockout of intracellular molecule SHP-1 enhances tumor-killing ability of CD133-targeted CAR T cells in vitro	6
Bispecific antibodies and dual-targeting CAR-T cells for multiple myeloma: latest updates from the 2023 ASCO annual meeting	6
Molecular subclassification of gastrointestinal cancers based on cancer stem cell traits	6
Sphingosine kinase 1 contributes to the metastatic potential of epithelial ovarian cancer to the adipocyte-rich niche	6
Overall survival of recurrent/metastatic head & neck squamous cell carcinoma patients progressing after ≥ 1 line of systemic therapy, treated with MVX-ONCO-1, a novel, first in class cell encapsul	6
Exploring neutrophil extracellular traps: mechanisms of immune regulation and future therapeutic potential	6
Role of the lectin pathway of complement in hematopoietic stem cell transplantation-associated endothelial injury and thrombotic microangiopathy	6
Targeting the integrated stress response in hematologic malignancies	6